AstraZeneca PLC (AZN)vsDecoy Therapeutics Inc. (DCOY)
AZN
AstraZeneca PLC
$157.24
-0.50%
HEALTHCARE · Cap: $243.86B
DCOY
Decoy Therapeutics Inc.
$3.58
+1.42%
HEALTHCARE · Cap: $2.16M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.0% profit margin vs 0.0%. DCOY trades at a lower P/E of 0.0x. AZN earns a higher WallStSmart Score of 65/100 (B-).
AZN
Strong Buy65
out of 100
Grade: B-
DCOY
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+20.4%
Fair Value
$196.68
Current Price
$157.24
$39.44 discount
Intrinsic value data unavailable for DCOY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : DCOY
The strongest argument for DCOY centers on P/E Ratio, Price/Book.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : DCOY
The primary concerns for DCOY are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while DCOY is a value play — different risk/reward profiles.
DCOY carries more volatility with a beta of 0.58 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (65/100 vs 26/100), backed by strong 17.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Decoy Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?